Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity, Inc. is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval.

Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions.

Key Stats

• Today's Range: $50.71 to $55.44
• 50-Day Range: $13.54 to $62.53
• 52-Week Range: $7.57 to $63.06
• Volume: 1.60 million shs
• Average Volume: 813,857 shs
• Market Capitalization: $2.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 28% of companies evaluated by MarketBeat, and ranked 805th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Buy

Consensus Rating

Celcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Celcuity is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Celcuity has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Celcuity are expected to decrease in the coming year, from ($2.62) to ($3.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 16.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.73% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Celcuity has recently increased by 19.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.73% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Celcuity has recently increased by 19.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.61

News Sentiment

Celcuity has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Celcuity this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for CELC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,818,744.00 in company stock.

Percentage Held by Insiders

15.77% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CELC Stock Analysis - Frequently Asked Questions

How have CELC shares performed this year?

Celcuity's stock was trading at $13.09 at the start of the year. Since then, CELC stock has increased by 296.3% and is now trading at $51.88.

How were Celcuity's earnings last quarter?

Celcuity, Inc. (NASDAQ:CELC) released its earnings results on Thursday, August, 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.14.
Read the conference call transcript.

When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's top institutional investors include Soleus Capital Management L.P. (7.74%), Perceptive Advisors LLC (4.20%), Eventide Asset Management LLC (3.57%) and Saturn V Capital Management LP (3.05%). Insiders that own company stock include Richard E Buller and David Dalvey.
View institutional ownership trends.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celcuity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/19/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CELC
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Celcuity: $56.50
• High Price Target: $70.00
• Low Price Target: $30.00
• Potential Upside/Downside: +8.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$111.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.07%
• Return on Assets: -64.67%

Debt

• Debt-to-Equity Ratio: 2.24
• Current Ratio: 4.58
• Quick Ratio: 4.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.11 per share
• Price / Book: 16.68

Miscellaneous

• Outstanding Shares: 42,430,000
• Free Float: 35,736,000
• Market Cap: $2.20 billion
• Optionable: Optionable
• Beta: 0.72